In the present study, we found that nab-paclitaxel treatment increased phosphorylation of Akt, mTOR, p70 S6K and 4E-BP1, a mechanism that could enhance tumor cell-related resistance to nab-paclitaxel. Here, RPS6KB1 is linked to neoplasm.